UPDATE: Immune Pharma Says Co. Plans To Timely Request A Hearing Before Nasdaq Listing Qualifications Panel, Which Will Stay Suspension, Any Delisting Action At Least Pending Issuance Of Panel Decision
Benzinga Newsdesk